Pioneering diagnostics


About half the world's population lives in malaria risk areas. Malaria is a preventable and curable infectious disease. Since 2000, significant progress has been made in the fight against malaria thanks to increased international funding and initiatives.

Key facts

  • 1 child dies from malaria every 60 seconds.
  • 219 million cases of malaria occur worldwide every year.
  • 104 malaria endemic countries.

Increase access to malaria diagnosis

An early malaria diagnosis allows the better treatment of the disease but also reduces the emergence of drug resistance. Since its publication on March 2010, the WHO has recommended to conduct a parasitological confirmation with a rapid test or a microscopic examination before any curative treatment*.

* World Health Organization; Guidelines for the treatment of Malaria - second edition; March 2010

Our commitment to the fight against Malaria

In January 2013, bioMérieux launched VIKIA® Malaria Ag Pf/Pan, the first rapid diagnostic test (RDT) in the tropical and neglected disease panel currently being developed through bioMérieux’s collaboration with IMAccess.

IMAccess is a subsidiary of the Institut Mérieux. The company adopted a “not-for-profit” business model dedicated to fighting infectious diseases in developing countries through the development of rapid diagnostic tests. IMAccess aims to increase access to the greatest number of people to reliable and accessible diagnostic tools.

VIKIA® Malaria Ag Pf/Pan complements an existing range of products for the diagnosis of infectious diseases such as HIV, Hepatitis, Tuberculosis.

Useful links:
Roll Back Malaria
World Health Organization: Malaria Fact sheet